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Background—A decrease in sarcoplasmic reticulum Ca21 pump (SERCA2) activity is believed to play a role in the
impairment of diastolic function of the failing heart. Because the expression ratio of phospholamban (PL) to SERCA2
may be a target to improve contractile dysfunction, a PL antisense RNA strategy was developed under the control of
either a constitutive cytomegalovirus (CMV) or an inducible atrial natriuretic factor (ANF) promoter. The latter is
upregulated in hypertrophied and failing heart, allowing “induction-by-disease” gene therapy.
Methods and Results—Part of the PL cDNA was cloned in antisense and sense directions into adenovectors under the
control of either a CMV (Ad5CMVPLas and Ad5CMVPLs, respectively) or ANF (Ad5ANFPLas and Ad5ANFPLs,
respectively) promoter. Infection of cultured rat neonatal cardiomyocytes with Ad5CMVPLas reduced PL mRNA to
3067% of baseline and PL protein to 2463% within 48 and 72 hours, respectively. The effects were vector dose
dependent. Ad5CMVPLas increased the Ca21 sensitivity of SERCA2 and reduced the time to 50% recovery of the Ca21
transient. A decrease of PL protein was also achieved by infection with Ad5ANFPLas, and the presence of the
hypertrophic stimulus, endothelin-1, led to enhanced downregulation of PL. The adenovectors expressing PL sense RNA
had no effect on any of the tested parameters.
Conclusions—Vector-mediated PL antisense RNA expression may become a feasible approach to modulate myocyte Ca21
homeostasis in the failing heart. The inducible ANF promoter for the first time offers the perspective for
induction-by-disease gene therapy, ie, selective expression of therapeutic genes in hypertrophied and failing
cardiomyocytes. (Circulation. 2000;101:2193-2199.)
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The heart adapts to increased workload by respondingto mechanical and endocrine, paracrine, and autocrine
factors that induce hypertrophy of ventricular myocytes.
Although this response is initially compensatory by in-
creasing cardiac output, sustained excessive workload
ultimately leads to heart failure.1 The b-adrenoceptor and
sarcoplasmic reticulum (SR) Ca21 pump (SERCA2) genes
are downregulated and the atrial natriuretic factor (ANF)
gene is strongly upregulated in hypertrophied and failing
human myocardium.2–5 The decrease in SR Ca21 pump
activity is believed to be involved in the diastolic dysfunc-
tion of the failing heart.1,4,5 The SR Ca21 pump in the
normal heart is inhibited by the regulatory protein phos-
pholamban (PL); this effect is relieved by b-adrenergic
stimulation.6 Studies on (heterozygous) PL-knockout and
PL-overexpressing mice have indicated that the expression
ratio of PL to SERCA2 is a potential target for improve-
ment of diastolic function of the failing heart.7 Cardiac
overexpression of SERCA2 and PL by efficient
adenovirus-mediated gene transfer indeed led to shorten-
ing and prolongation of the relaxation phase, respective-
ly.8,9 These studies used viral promoters, resulting in
ubiquitous and constitutive transgene expression. Cardiac
troponin T and myosin heavy- and light-chain promoters
have also been applied, but only the latter displayed
reporter activity exclusively in ventricles.10,11
Received October 4, 1999; revision received December 7, 1999; accepted December 22, 1999.
From the Department of Biochemistry, Cardiovascular Research Institute COEUR, Erasmus University Rotterdam (K.E., K.B., J.M.J.L.), and the
Department of Cardiology, Leiden University Medical Center (A.v.d.L.), Netherlands; and the Department of Cardiology and Pneumology, University
Hospital Benjamin Franklin, Free University Berlin (H.F., S.S.-R., H.W., H.-P.S, W.C.P.), Germany.
Correspondence to J.M.J. Lamers, PhD, Department of Biochemistry, Cardiovascular Research Institute (COEUR), Faculty of Medicine and Health
Sciences, Erasmus University, PO Box 1738, 3000 DR Rotterdam, Netherlands. E-mail lamers@bc1.fgg.eur.nl
© 2000 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org
2193
In this study, we used an antisense RNA strategy directed
against de novo synthesis of PL under control of cytomega-
lovirus (CMV) or ANF promoter. The latter is strongly
upregulated in hypertrophied and failing myocardium and
therefore is used to evaluate the concept of “induction-by-
disease” gene therapy.3,5 Many studies on signaling involved
in hypertrophy and changes in gene expression have used the
model of cultured neonatal rat cardiomyocytes stimulated by
stretch or agonists such as endothelin-1 (ET-1).12–14 There-
fore, this model was used to test the effectiveness of the
newly developed adenovectors on PL expression, SR Ca21
uptake activity, and Ca21 transients.
Methods
Materials
Culture dishes (Costar catalogue No. 3506 and NUNC, catalogue
No. 176740) from Becton Dickinson, culture media DMEM and
M199 from Gibco-BRL, and fetal bovine and horse sera and all
molecular biology enzymes from Boehringer were used. Cloning
plasmids were from Promega and Microbix, ET-1 from Peninsula
Laboratories, [32P]dCTP and 45Ca from Amersham, and 125I-labeled
goat antimouse IgG from ICN.
Isolation of PL cDNA
PL cDNA was obtained by screening of a rat cDNA library (Lambda
ZAP, Stratagene) with a probe derived from genomic DNA contain-
ing promoter and exon 1 of PL (unpublished). One cDNA (clone
321, 586 bp) appeared to be identical to previously published
sequences, with minor differences in the 39 trailer,15 and was used for
construction of the adenovirus shuttle plasmids.
Development of Recombinant Adenoviral Vectors
Recombinant adenoviral vectors expressing a partial PL antisense
mRNA (Ad5CMVPLas) or sense mRNA (Ad5CMVPLs), respec-
tively, under the control of a CMV promoter were developed.16,17 A
230-bp EcoRI-TaqI fragment of PL cDNA containing the translation
start codon (Figure 1) was inserted into the polylinker of pCMVI in
antisense or sense orientation. The resulting CMV promoter expres-
sion plasmids were cotransfected with circularized adenoviral ge-
nome pJM17 into 293 cells. Viral plaques appeared between 10 and
20 days and were screened for recombinant virus.16,17 Recombinant
vectors expressing a partial PL antisense RNA (Ad5ANFPLas) or
sense (Ad5ANFPLs) RNA, respectively, under control of an ANF
promoter were developed as follows: The ANF promoter (680-bp
EcoRI-BamHI), a kind gift from K.R. Chien (University of Califor-
nia, San Diego), was first cloned in pCAT3 (ANF-CAT) to prove its
ET-1 inducibility in rat cardiomyocytes transfected by gene gun
biolistics by use of a chloramphenicol acetyltransferase (CAT)
ELISA assay (Boehringer).18–20 The partial PL cDNA was inserted
into the ANF-CAT plasmid in antisense or sense orientation, thereby
eliminating the CAT reporter and introducing a chimeric intron
between ANF promoter and PL cDNA. Next, EcoRI-BamHI frag-
ments (1521 bp) containing the ANF promoter, followed by the
partial PL cDNA and the SV40 poly-A signal, were cloned into the
plasmid pDE1sp1A yielding transfer plasmids with structures similar
to those used for Ad5CMVPLs and Ad5CMVPLas, but with ANF
instead of CMV promoter. After cotransfection with pJM17 into 293
cells, viral plaques were screened for recombinant virus. Purified
positive plaques were grown in large quantities on 293 cell cultures
and purified by standard CsCl ultracentrifugation and desalting.16,17
Absence of replication-competent adenovirus was confirmed by
polymerase chain reaction (PCR) for the wild-type adenoviral E1
region and by high-titer infections of nonpermissive EAhy.926 and
CHO cells (multiplicity of infection [MOI] 10). Virus titers deter-
mined by plaque assay and vector doses are expressed as MOI,
defined as plaque-forming units per cell.
Preparation and Adenoviral Infection of Myocytes
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85-23, revised 1996). Rat
neonatal ventricular myocytes were isolated,21 preplated, and cul-
tured in 1.8-cm2 (Western blotting), 10-cm2 (Ca21 transient measure-
ments), or 20-cm2 (Northern blotting and Ca21 uptake measurements)
dishes (7.53104 cells/cm2 for the Ad5ANFPLas and Ad5ANFPLs
infections and 1.53105 cells/cm2 for the Ad5CMVPLas and
Ad5CMVPLs infections, except for the Ca21 transient measure-
ments: 0.33105 cells/cm2), up to 24 hours in DMEM/M199 (4:1)
supplemented with 5% FCS and 5% horse serum and up to 64 hours
with only 5% horse serum. Subsequently, infections were started in
200 mL (1.8-cm2 dishes) or in 600 mL (20-cm2 dishes) serum-free
medium for 3 hours and continued for 72 hours after addition of 600
or 2600 mL serum-free medium, respectively. When appropriate,
after 3 hours, ET-1 (1028 mol/L) was added to induce hypertro-
phy.13,18,19,21 Analyses in addition to the plaque assays were carried
out to confirm that the relative functional activities of the viruses
closely matched: (1) CMV vector doses were tested at the RNA level
by hybridizing Northern blots (Figure 2) with SV40 probe specifi-
cally recognizing vector-derived RNA, and similar transcriptional
activities (relative to GAPDH) were found; and (2) ANF vectors,
because of their low expression levels, were tested instead by
semiquantitative PCR of infected cells, followed by gel electrophore-
sis and quantification of the PCR products (not shown).
Northern Blotting
Total cardiomyocyte RNA was isolated by the guanidinium isothio-
cyanate method, separated on 1% denaturing formaldehyde-agarose
gels, and blotted onto Hybond (Amersham). Probes were labeled by
random priming with [a-32P]dCTP: PL; the TaqI-EcoRI fragment of
the PL cDNA (excluding the part used for the constructs, Figure 1);
GAPDH, developed by RT-PCR on rat heart RNA; and SV40, the
SV40 poly A fragment of pCMVI plasmid. Hybridization and
washing were carried out as described.13 Hybridization signals were
quantified by Molecular Imager (BioRad) and corrected for GAPDH.
Two bands were detected with the PL probe and coquantified.
Western Blotting
Cardiomyocytes were homogenized into 10 mmol/L Tris-HCl, 0.3
mol/L sucrose, 1 mmol/L dithiothreitol, and 3 mmol/L NaN3 by
freeze-thawing. Protein (10 mg) in SDS loading dye (not boiled) was
Figure 1. Graphical representation of PL cDNA (top line) and
adenovectors. Coding region is indicated as vertically striped
box. EcoRI-TaqI fragment harboring 59-untranslated and only 47
bp of coding region was used for adenoviral constructs. Names
(left) of adenoviral constructs and their compositions (right) are
given. B indicates BamHI; C, ClaI; E, EcoRI; H, HindIII; T, TaqI;
and X, XbaI. Brackets indicate sites lost during cloning. Num-
bers indicate lengths in kb.
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separated with an SDS-PAGE 7.5% to 15% gradient gel and blotted
onto PVDF (Amersham). Blots were incubated with monoclonal
anti-PL (1:2500) (clone 20/2 [Affinity Bioreagents]) or anti-
SERCA2 (1:1000) (clone 2A7-A1, BIOMOL Research Laboratory)
as primary antibody followed by 125I-labeled goat antimouse IgG
(1:1000) as secondary antibody. After washing, blots were quantified
in the molecular imager. The major band (pentameric form of PL,
PLV) was quantified.
Ca21 Affinity of the SR Ca21 Pump
Oxalate-dependent and thapsigargin (1 mmol/L)–sensitive Ca21 up-
take activity at different free Ca21 concentrations was measured in
infected and noninfected cardiomyocyte homogenates.22 Briefly,
cardiomyocytes were frozen in liquid N2 and homogenized in 100
mL 0.3 mol/L sucrose, 20 mmol/L imidazole (pH 7.0), and
10 mmol/L Na2S2O5 (to stabilize SR Ca21 pump23) with a microdis-
membrator (Braun). Protein (20 mg) was preincubated at 37°C for 2
minutes in 410 mL 2.5 mmol/L ATP, 50 mmol/L KCl, 10 mmol/L
imidazole (pH 7.0), 2.5 mmol/L MgCl2, 5 mmol/L potassium
oxalate, and 10 mmol/L ruthenium red. The reactions were started by
addition of 40 mL 45Ca21 (0.2 Ci/mmol)–EGTA (1 mmol/L) buffers,
of which the pCa’s were 7, 6.5, 6, and 5. The free Ca21 concentra-
tions were calculated by the computer program WinMAXC version
1.75 (www.stanford.edu/;cpatton) with the following dissociation
constants: Ca21-EGTA, 3.8831027 mol/L; Ca21-ATP, 8.1631025
mol/L; Mg21-EGTA, 3.1031022 mol/L; and Mg21-ATP, 6.8631025
mol/L. Aliquots (100 mL) were filtered after 1, 2, and 4 minutes
through 0.45-mm Millipore filters, and 45Ca was measured by liquid
scintillation counting.
Ca21 Transients of Cardiomyocytes
Infected and noninfected beating cardiomyocytes were cultured on
5-cm2 glass coverslips in 10-cm2 dishes, washed with HEPES-
buffered salt solution (HBSS) containing (in mmol/L) NaCl 125,
KCl 5, MgSO4 1, KH2PO4 1, CaCl2 2.5, NaHCO3 10, HEPES 20, and
probenecid 2.5, pH 7.4, and loaded in HBSS containing 2 mmol/L
fura 2-AM (Molecular Probes, Eugene) and 5 mmol/L glucose for 45
minutes at 37°C. Subsequently, the cells were washed, and the
coverslip was fitted in a Teflon culture dish,24,25 incubated in 1 mL
5 mmol/L glucose containing HBSS in a thermostatted chamber, and
mounted on the stage of a fluorescence microscope (Leitz Diavert).
Fluorescence was recorded at 360- and 380-nm excitation wave-
lengths with a 490-nm high-pass filter in the emission path with a
sensitive video camera (Hamamatsu C2400-08). The mean gray level
of video line segments enclosed by the region of interest was
sampled at a frequency of 50 Hz by computer. First, the dark current
of the camera was recorded and stored, for which fluorescence
intensities were corrected. Second, fluorescence at 360 nm was
recorded, by which fluorescence at 380 nm was divided and stored as
F380/F360 ratios. These ratios produce signals nonlinearly related to
[Ca21]i. The time to 50% recovery of the Ca21 transient, but not the
time to peak of the Ca21 transient, was dependent on beating
frequency. Therefore, myocytes were always stimulated electrically
at 1 Hz by 2 platinum electrodes.
Statistical Analysis
One-way ANOVA was performed, followed by multiple comparison
by Student-Newman-Keuls test, with the statistical computer pro-
gram SigmaStat. Significance was set at P,0.05 for $4 independent
experiments.
Results
Cellular PL mRNA and Protein
Cardiomyocytes were infected with 2 different doses of the
vectors Ad5CMVPLas and Ad5CMVPLs (MOI 5 and 10) to
study their effects on PL expression. A marked and vector-
dose–dependent reduction in PL mRNA is apparent after 24
hours of infection with Ad5CMVPLas (88614% and
68619% left at MOI 5 and 10, respectively) and becomes
more pronounced after 48 hours (5361% and 3067% left,
respectively) (Figure 2). Subsequently, we examined the
effect of the CMV vectors on PL protein. A significant
decrease in PL protein content was first visible 48 hours after
infection with Ad5CMVPLas (90611% [P5NS], 6363%,
and 5566% left at MOI 2.5, 5, and 10, respectively),
becoming more pronounced after 72 hours (6969%,
42610%, and 2463% left, respectively) (Figure 3). Like
control cells, incubation with Ad5CMVPLs virus produced
no effects, indicating specificity of the antisense effect.
Cellular SR Ca21 Pump Activity and
SERCA2 Protein
We measured oxalate- and ATP-dependent Ca21 uptake in
homogenates of control and infected cardiomyocytes at dif-
ferent nonsaturating free [Ca21]i (pCa 5 to 7). No significant
effect of Ad5CMVPLas (MOI 10) on Ca21 uptake activity
was seen 48 hours after infection (Figure 4A), but at 72 hours,
the relative Ca21 uptake activity at pCa 6.5 was significantly
increased compared with control and Ad5CMVPLs-infected
cells (Figure 4B). No effect of Ad5CMVPLas was seen at
pCa 6, when Ca21 uptake activity is closer to maximum
reached at pCa 5. After 72 hours, Ad5CMVPLas reduced
maximal Ca21 pump activity, which cannot be explained by
cell loss, because total protein content remained unchanged
(legend to Figure 4). A partial reduction of SERCA2 protein
after 72 hours of Ad5CMVPLas infection (57.966.4% left,
Figure 2. Levels of PL mRNA 24 and 48 hours after infection of
cardiomyocytes with Ad5CMVPLas vs Ad5CMVPLs at 2 different
doses (MOI 5 and 10). A, Northern blot of a representative
experiment (Ad5CMVPLas at MOI 10). C indicates incubation
without virus, and duplicate measurements are shown. Markers
18S and 28S are indicated on left. B, Graphical representation
of mean PL/GAPDH mRNA ratios expressed as % (6SEM) of
control cells obtained from $4 independent experiments.
*P,0.05 vs control cells.
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P,0.05 versus uninfected or Ad5CMVPLs-infected cells)
was observed, however, which may explain the decrease of
maximal Ca21 uptake activity (Figure 5).
Ca21 Transients After Infection
With Ad5CMVPLas
To determine whether depletion of PL protein by
Ad5CMVPLas also alters the duration of the Ca21 transient of
intact cardiomyocytes, the specific fluorescence of fura
2–loaded cells was recorded at fixed beating frequency (1
Hz). Time to 50% recovery of Ca21 transients was already
lower after 48 hours in Ad5CMVPLas (MOI 5)–infected cells
(245698 ms; n542, P,0.05 versus uninfected and
Ad5CMVPLs-infected cells) compared with uninfected
(593688 ms; n54) and Ad5CMVPLs-infected cells
(564638 ms; n57), indicating that by decrease of PL
content, the removal rate of Ca21 from myofilaments during
relaxation of the cardiomyocytes is increased (see represen-
tative average Ca21 transient recordings in Figure 6).
Cellular PL Protein After Infection
With Ad5ANFPLas
The ANF promoter fragment used was first tested for ET-1
responsiveness and displayed low activity in nonstimulated
gene-gun–transfected cardiomyocytes.18,19 On ET-1 (1028
mol/L) stimulation, the promoter activity increased 2.5-
fold.18 Figure 6 depicts PL protein expression obtained 48 and
72 hours after infection with Ad5ANFPLas (MOI 10) with or
without ET-1 stimulation. Earlier, we showed that in un-
stimulated cells, ANF mRNA is present in low but significant
amounts.13,19 This explains the decrease in PL protein that
was measured in Ad5ANFPLas-infected cells also in the
absence of ET-1 (Figure 7, at 72 hours, 8666% left versus
noninfected cells). However, Ad5ANFPLas in the presence
of ET-1 resulted in a significant further reduction of PL
protein (7267% left). Ad5ANFPLs had no effect, indicating
specificity of the antisense effect.
Discussion
Infection of cardiomyocytes with Ad5CMVPLas resulted
in a dramatic decrease in endogenous PL mRNA expres-
sion after 48 hours, presumably by increased degradation
of the message. The vector generating partial sense mRNA
and perhaps truncated PL protein clearly had no effect on
endogenous PL mRNA or protein, indicating the specific-
ity of the antisense effect. Downregulation of PL protein
Figure 3. Levels of PL protein 24, 30, 48, and 72 hours after
infection of cardiomyocytes with Ad5CMVPLas vs Ad5CMVPLs
at 2 different doses. A, Western blot of a representative experi-
ment at MOI 10. C indicates incubation without virus. B, Graphi-
cal representation of mean PL protein levels expressed as %
(6SEM) of uninfected cells obtained from $5 independent
experiments. *P,0.05 vs control cells, #P,0.05 vs
Ad5CMVPLas (MOI 2.5), 0P,0.05 vs Ad5CMVPLas (MOI 5).
Figure 4. SR Ca21 uptake activity as % of maximal after 48 and
72 hours in noninfected and Ad5CMVPLas- or Ad5CMVPLs-
infected (both MOI 10) cardiomyocytes. Maximal activities at
pCa 5 (nmol Ca21 z mg protein21 z min21) 48 hours after infection
were control, 12.8061.90; Ad5CMVPLas, 13.060.99; and
Ad5CMVPLs, 15.2062.38; and 72 hours after infection, control,
12.6361.00; Ad5CMVPLas, 7.5260.60 (P,0.05 vs control and
Ad5CMVPLs); and Ad5CMVPLs, 16.7061.84 (P5NS vs control
and P,0.05 vs Ad5CMVPLas). Protein contents (mg/mL) of ho-
mogenates 48 hours after infection were control, 2.0160.37;
Ad5CMVPLas, 2.3960.26; and Ad5CMVPLs, 2.4460.28; and 72
hours after infection, control, 2.5260.12; Ad5CMVPLas,
2.9160.15; and Ad5CMVPLs, 2.9960.10. Values are
mean6SEM of samples from 6 (48 hours) or 5 (72 hours) inde-
pendent experiments. *P,0.05 vs control and Ad5CMVPLs-
treated cells.
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lags ’24 hours behind that of PL mRNA, indicating that
no compensatory posttranscriptional mechanisms are
present.
Downregulation of SERCA2 in hypertrophied and/or fail-
ing myocardium is believed to play a role in the diastolic
dysfunction. Several studies reported downregulation of PL
in failing heart as well, but generally not as much as
SERCA2.4,5 Because PL in anomalous phosphorylation states
may also occur in severe heart failure,26 antisense suppression
of the endogenous PL gene may have an advantage over the
enhancement of SERCA2 gene expression. Gene enhance-
ment will not influence preexisting malfunctioning endoge-
nous gene products, whereas antisense-based gene suppres-
sion can do so. The reduced expression of PL caused by
Ad5CMVPLas results in increased Ca21 affinity of the SR
Ca21 pump and in decreased time to 50% recovery of the Ca21
transients of intact cells. This is consistent with a very recent
report by He et al,27 who showed increased shortening as well
as relengthening velocity in adult rabbit cardiomyocytes
infected with an adenovector expressing a dominant negative
mutant PL protein. However, in our present study on mono-
layer cultures of cardiomyocytes, we were unable to measure
relative shortening of the cells during stimulation, because
rhythmic displacement of cell boundaries is hard to relate to
initial length of the myocytes concerned. Moreover, extrap-
olation of results on contractile motion of unloaded myocytes
to the in vivo situation is doubtful.
Ad5CMVPLas infection (72 hours) of cardiomyocytes not
only increased the Ca21 affinity of SR Ca21 pump but also
partially reduced its maximal activity. The latter effect is
probably due to decreased SERCA2 expression (Figure 5). At
present, it is unclear whether this adenovector effect indicates
counterregulatory systems in cardiac Ca21 homeostasis.
Conversely, by suppression of endogenous PL protein, the
b-adrenergic response becomes blunted. In failing myocardi-
um, however, b-adrenoceptors are reduced and the associated
regulatory components functionally altered, causing the at-
tenuated b-adrenergic response.2 Interestingly, myocytes iso-
lated from hearts of PL-knockout mice retained the relaxant
effect evoked by catecholamine.28 Troponin I phosphoryla-
tion may increase the “off rate” for Ca21 exchange, with
troponin C compensating for the effect of PL ablation on the
b-adrenergic response.
Our development of inducible ANF promotor vectors for
induction-by-disease gene therapy takes advantage of the
fact that the cardiac hypertrophic phenotype in vivo and in
vitro is characterized by transcriptional upregulation of
distinct genes.3,5,12,13,19,20 Unlike the in vivo situation, a
low expression of ANF is present in nonstimulated cardio-
myocytes,12–14,19 which explains the small reduction by
treatment with Ad5ANFPLas even in the absence of ET-1.
In the presence of ET-1, however, a stronger reduction of
PL protein was observed, consistent with the known ET-1
responsiveness of the ANF promoter.12–14 These results are
a first demonstration in cardiomyocytes of the feasibility
of using a heart-specific promoter that becomes activated
when the cells become hypertrophic. Another advantage is
the expected return of this promoter to minimal activity
Figure 5. Levels of SERCA2 (and PL) protein 48 and 72 hours
after infection of cardiomyocytes with Ad5CMVPLas vs
Ad5CMVPLs at MOI 10. Protein levels are expressed as %
(6SEM) of uninfected cells obtained from 6 independent experi-
ments. *P,0.05 vs control cells, #P,0.05 vs Ad5CMVPLs
infected cells.
Figure 6. Ca21 transients, represented by time-dependent
changes in F380/F360 of fura 2–loaded cardiomyocytes stimulated
at 1 Hz, of uninfected cardiomyocytes (top) and cardiomyocytes
infected with Ad5CMVPLas (middle) and Ad5CMVPLs (bottom)
at MOI 5 for 48 hours. To improve signal-to-noise ratio, 5 to 10
subsequent Ca21 transients were averaged per panel. Times to
50% recovery of Ca21 transients are 719 ms (top), 398 ms (mid-
dle), and 615 ms (bottom). Note that F380/F360 is an inverse mea-
sure of intracellular free Ca21 concentration.
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when the myocytes improve in contractile function be-
cause of treatment. Knowlton et al29 tested the same rat
ANF promoter in transgenic mice with hypertrophy in-
duced by pressure overload. In this model, the rat ANF
promoter did confer cell-specific expression but not induc-
ibility on pressure overload. Possibly, transgenic mice may
compensate for the effects of the transgene during devel-
opment, or species difference of rat promoter versus
transgenic mice may be responsible for the lack of induc-
ibility.29 Hajjar et al30 first described a method yielding
high adenovector transfer rates in vivo specifically to the
rat ventricles. We could confirm those findings using an
adenovector expressing green fluorescent protein, thus
opening a way to test the PL antisense adenovectors in
vivo.31 In conclusion, the present study suggests that
vector-mediated PL antisense RNA expression may be-
come a feasible approach to improve contractile dysfunc-
tion of the failing heart. The inducible ANF promoter
offers the perspective for induction-by-disease gene ther-
apy by selective expression of therapeutic genes in the
hypertrophied and failing myocytes.
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